论文部分内容阅读
目的:观察联合应用瑞格列奈和二甲双胍治疗肥胖2型糖尿病的临床效果。方法:选择我科84例肥胖2型糖尿病为研究对象,随机分为对照组和研究组,每组各42例,对照组单纯应用瑞格列奈治疗,研究组联合应用瑞格列奈+二甲双胍治疗,比较两组临床治疗效果。结果:治疗2个月后,研究组FPG、HbAlc、BMI值均显著优于对照组(p<0.05);研究组不良反应发生率为7.32%,对照组为9.52%,组间比较无显著差异(P>0.05)。结论:联合应用瑞格列奈和二甲双胍治疗肥胖2型糖尿病效果明显,能够有效改善患者血糖、BMI水平,且不良反应少,值得在临床中推广。
Objective: To observe the clinical effect of combined use of repaglinide and metformin in the treatment of obese type 2 diabetes mellitus. Methods: Eighty-four cases of obese type 2 diabetes mellitus were selected as study subjects and randomly divided into control group and study group, with 42 cases in each group. The control group was treated with repaglinide alone. The study group was treated with repaglinide + metformin Treatment, compared the clinical treatment effect of two groups. Results: At 2 months after treatment, the FPG, HbAlc and BMI in the study group were significantly better than those in the control group (p <0.05). The incidence of adverse reactions was 7.32% in the study group and 9.52% in the control group, with no significant difference between the two groups (P> 0.05). Conclusion: The combination of repaglinide and metformin is effective in treating obese type 2 diabetes mellitus, which can effectively improve the blood sugar and BMI levels of patients with less adverse reactions and is worth popularizing in clinic.